Renovaro Inc. Files 10-K/A Amendment

TL;DR

Renovaro Inc. (formerly Enochian) filed its 2024 10-K/A. Check for updates.

AI Summary

Renovaro Inc. filed an amendment (10-K/A) to its annual report for the fiscal year ended June 30, 2024. The company, formerly known as Enochian Biosciences Inc. and Renovaro Biosciences Inc., is incorporated in Delaware and operates in the Pharmaceutical Preparations sector. The filing was made on October 28, 2024, with its principal business address in Los Angeles, California.

Why It Matters

This amendment provides updated information for the fiscal year 2024, which is crucial for investors to assess the company's financial health and strategic direction.

Risk Assessment

Risk Level: medium — As an amendment to an annual report, it may contain significant updates or corrections to previously disclosed information, requiring careful review.

Key Numbers

• 20240630 — Fiscal Year End (The period covered by the annual report.)
• 20241028 — Filing Date (The date the amendment was submitted to the SEC.)

Key Players & Entities

• RENOVARO INC. (company) — Registrant
• Enochian Biosciences Inc. (company) — Former company name
• Renovaro Biosciences Inc. (company) — Former company name
• 20240630 (date) — Fiscal year end
• 20241028 (date) — Filing date
• 001-38758 (dollar_amount) — SEC file number

FAQ

Key Financial Figures

• $0.0001 — ch Registered Common Stock, par value $0.0001 per share RENB The Nasdaq Stock Mar
• $57,193,356 — ommon equity held by non-affiliates was $57,193,356. As of October 27, 2024, the number of
• $300 million — es, Mr. Weinstein directly sourced over $300 million in investments for small-cap biotech an
• $650 million — nership deals with Genentech worth over $650 million in upfront and milestone payments. Duri
• $430,000 — , which called for cash compensation of $430,000 per annum, and the grant of options to
• $8.00 — es of common stock at a strike price of $8.00 per share on June 11, 2020. On October

Filing Documents

• e6062_10ka.htm (10-K/A) — 213KB
• e6062_ex31-1.htm (EX-31.1) — 9KB
• e6062_ex31-2.htm (EX-31.2) — 9KB
• e6062_ex97-1.htm (EX-97.1) — 29KB
• 0001731122-24-001664.txt ( ) — 261KB

Directors, Executive Officers and Corporate Governance

Item 10. Directors, Executive Officers and Corporate Governance 1

Executive Compensation

Item 11. Executive Compensation 5

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 9

Certain Relationships and Related Transactions and Director Independence

Item 13. Certain Relationships and Related Transactions and Director Independence 11

Principal Accounting Fees and Services

Item 14. Principal Accounting Fees and Services 13

Exhibits, Financial Statement Schedules

Item 15. Exhibits, Financial Statement Schedules 14 i PART III

Directors, Executive Officers and Corporate Governance

Item 10. Directors, Executive Officers and Corporate Governance Identification of Directors The following is a description of the business experience, qualifications, skills, and educational background of each of our directors, including each director's relevant business experience: David Weinstein On October 14, 2024, the board of directors of the Company appointed David Weinstein, age 64, Chief Executive Officer of the Company and a member of the Board. Immediately prior to joining the Company, Mr. Weinstein was a Managing Partner, Investment Banking at Dawson James Securities, Inc. where he has worked since 2005. While at Dawson James, Mr. Weinstein directly sourced over $300 million in investments for small-cap biotech and healthcare companies. He also spearheaded the merger of two healthcare companies in personalized cancer diagnostics and assisted in its uplisting on Nasdaq. Mr. Weinstein received his Bachelor of Arts in Liberal Arts from St. John's College and a Masters in Public Management from the University of Maryland. Maurice van Tilburg Maurice van Tilburg has held several senior positions in the Financial Services industry and Tech enterprises combining general management, technology, operational service delivery, financial management, audit and product development. He is also an awarded artist that combines leadership roles in the industry with a successful series of art concepts. Mr. van Tilburg currently serves as the Director of the Dutch National Growth fund where he oversees the largest government investments in the area of innovation and technology. With this he builds on his role at Techleap.nl where he developed new and additional sources of funding for Dutch Tech scale ups in order to contribute to global challenges, economic growth, technology capabilities and employment in The Netherlands. Mr. van Tilburg brings with him his experience as CEO of Euronext Amsterdam where he was responsible for clients, product development, organiza

Executive Compensation

Item 11. Executive Compensation Name and Principal Position Year Salary ($) Bonus Stock Awards ($) Option Awards ($)(1) Non-equity incentive plan compensation ($) Other Compensation ($) Total ($) Mark Dybul, M.D. 2024 $ 325,282 $ — $ — $ 1,434,044 $ — $ — $ 1,660,906 Chief Executive Officer (2) 2023 $ 664,583 $ 100,000 $ — $ 640,850 $ — $ — $ 1,405,433 Francois Binette 2024 $ 402,500 $ — $ — $ 27,790 $ — $ — $ 430,290 Chief Operating Officer &EVP-R&D 2023 $ 389,375 $ 115,000 $ — $ 377,195 $ — $ — $ 881,570 Luisa Puche 2024 $ 289,214 $ — $ — $ 38,978 $ — $ — $ 328,192 Chief Financial Officer (3) 2023 $ 325,000 $ 185,000 $ — $ 130,000 $ — $ — $ 640,000 Simon Tarsh 2024 $ 93,750 $ — $ — $ 24,330 $ — $ — $ 118,080 Chief Financial Officer (4) 2023 $ — $ — $ — $ — $ — $ — $ — (1) The amounts shown do not reflect compensation actually received by the executive officer. Instead, the amounts shown are the total grant date valuations of stock option grants awarded during the year as determined pursuant to ASC Topic 718. The valuations are expensed for financial reporting purposes over the vesting period of the grant. (2) Effective October 14, 2024, Dr. Dybul resigned from the Company. (3) Effective March 21, 2024, Ms. Puche resigned from the Company. (4) Effective March 11, 2024, Mr. Tarsh was appointed as interim Chief Financial Officer. 5 Arrangements with Named Executive Officers During the fiscal year ended June 30, 2024, we had agreements in place with Dr. Dybul, Mr. Binette, Ms. Puche and Mr. Tarsh. A description of each agreement is set forth below. Mark R. Dybul, M.D. Since January 7, 2019, when Dr. Dybul became our principal executive officer by virtue of his appointment as Executive Vice-Chair of the Board, Dr. Dybul received compensation as Executive Vice Chair of the Board under his Amended and Restated Director's Agreement, as amended on May 1, 2019 (the

View Full Filing

View this 10-K/A filing on SEC EDGAR